Psoriasis-Arthritis: Wichtiges für den Dermatologen

Zusammenfassung

Die Psoriasis-Arthritis ist eine häufige und oft schwer verlaufende Gelenkerkrankung. Sie tritt fast ausschließlich zusammen mit der Psoriasis (der Haut) auf, wobei in den meisten Fällen der Hautbefall dem Gelenkbefall vorausgeht. Dem Dermatologen kommt somit eine wichtige Rolle im Management dieser Erkrankung zu: Durch eine frühe Diagnosestellung kann er maßgeblich zu einem optimalen Therapieerfolg beitragen. Dabei können Fragebögen hilfreich sein. Auch für die Therapie der Psoriasis der Haut beeinflusst ein zusätzlicher Gelenkbefall die Therapieentscheidung nachhaltig. In diesem Zusammenhang sollten auch Dermatologen wissen, welche klinischen Formen der Psoriasis-Arthritis nicht auf „konventionelle“ Antirheumatika ansprechen. Einige Grundkenntnisse zu Klinik, Diagnostik und Therapie der Psoriasis-Arthritis sind also auch für Dermatologen wichtig und werden in dieser Übersichtsarbeit zusammengestellt.

Abstract

Psoriatic arthritis is a common and often severe joint disease. It is almost exclusively associated with psoriasis (of the skin), with the skin symptoms usually preceeding joint manifestations by several years. Dermatologists thus play an important role in the management of this disease: Early diagnosis allows for timely intervention which in turn yields better outcomes. Screening questionnaires may help in this regard. Presence of joint symptoms also affects treatment decisions for psoriasis (of the skin). Dermatologists should therefore know which clinical manifestations of psoriatic arthritis do not respond to “conventional” anti-rheumatic drugs. Hence, some basic knowledge of clinic, diagnostics, and therapy of psoriatic arthritis is essential for dermatologists and will thus be summarized in this review.

• Literatur

• 1 Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78
• 2 Frediani B, Allegri A, Falsetti P et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001; 28: 138-143
• 3 Harrison BJ, Hutchinson CE, Adams J et al. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 2002; 61: 1007-1011
• 4 Borman P, Babaoglu S, Gur G et al. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 2008; 27: 443-447
• 5 Attia EA, Khafagy A, Abdel-Raheem S et al. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. Int J Dermatol 2011; 50: 30-35
• 6 Rohekar S, Tom BD, Hassa A et al. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008; 58: 82-87
• 7 Burmester GR, Mease P, Dijkmans PA et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-1869
• 8 Spadaro A, Scrivo R, Spinelli FR et al. Monitoring biological therapies in psoriatic arthritis. J Rheumatol 2009; 83: 69-70
• 9 Gisondi P, Tessari G, Conti A. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73
• 10 Eder L, Zisman D, Barzlai M et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008; 35: 877-882
• 11 Abuabara K, Azfar RS, Shin DB et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-592
• 12 Mallbris L, Granath F, Hamsten A et al. Psoriasis is associated with lipid abormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621
• 13 Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis in-patients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230
• 14 Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary arterial calcification. Br J Dermatol 2007; 156: 271-276
• 15 Jamnitski A, Symmonds D, Peters MJL et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72: 211-216
• 16 Qureshi AA, Dominguez P, Duffin KC et al. Psoriatic arthritis screening tools. J Rheumatol 2008; 35: 1423-1425
• 17 Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736-740
• 18 Wilson FC, Icen M, Crowson CS et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009; 61: 233-239
• 19 Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394
• 20 Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12
• 21 Gerdes S, Zahl VA, Knopf H et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008; 159: 1116-1123